SEC Tracker
Get the app

Capricor Therapeutics CAPR

Capricor Therapeutics reports third quarter 2026 financial results

Capricor Therapeutics (CAPR) filed an 8-K with the SEC on Nov 10, 2026, 4:06 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. BLA for Deramiocel under FDA review with PDUFA target action date of November 22, 2026
  2. Two-year HOPE-3 OLE data showed 76% slower upper limb decline after switching to Deramiocel
  3. Cash and cash equivalents of approximately $199 million as of September 30, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Capricor Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.